Your AI-Trained Oncology Knowledge Connection!

Abdulraheem Yacoub, MD

home / authors / abdulraheem-yacoub-md

Articles

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

August 7th 2023

The panel closes their discussion by highlighting novel agents in the treatment of myeloproliferative neoplasms to look out for.

Symptom Monitoring in Patients with MF

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

August 7th 2023

The panel explains the standards for symptom assessment in patients with myelofibrosis and how often patients are monitored.

Considering Toxicities and Side Effects of JAK Inhibitors in Patients with MF

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 31st 2023

Abdulraheem Yacoub, MD, details the side effect profiles of the approved JAK inhibitors for myelofibrosis treatment.

Sequencing Therapies in Patients with MF

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 31st 2023

Dr Jamile Shammo discusses how to approach sequencing therapies in patients with myelofibrosis and Dr Raajit Rampal explains the potential of the JAK inhibitor momelotinib in the treatment of myelofibrosis.

Pacritinib and Fedratinib for the Treatment of MF

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 24th 2023

Raajit Rampal, MD, and Abdulraheem Yacoub, MD, review data on the use of pacritinib and fedratinib in patients with myelofibrosis.

COMFORT-I and COMFORT-II Data Review

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 24th 2023

Jamile Shammo, MD, comments the currently approved treatment options for patients with myelofibrosis and review data from the COMFORT-I and COMFORT-II trials, which evaluates the use of ruxolitinib in MF.

The Role of Transplant in the Treatment of Patients With MF

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 17th 2023

Dr Abdulraheem Yacoub explains allogeneic hematopoietic cell transplantation in myelofibrosis, the only known curative treatment modality.

Reviewing the Types of Myelofibrosis

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 17th 2023

The panel reviews the types of myelofibrosis, discusses how to risk stratify and explains the role of biomarker testing in patients with MF.

Ropeginterferon alfa-2b for the Treatment of PV

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 10th 2023

Dr Jamile Shammo reviews recent data on the treatment of patients with polycythemia vera with ropeginterferon.

Ruxolitinib for the Management of PV

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 10th 2023

Abdulraheem Yacoub, MD, reviews data from the RESPONSE and RESPONSE-2 trials on the use of ruxolitinib for the treatment of polycythemia vera.

Selecting a Frontline Therapy for Patients With PV

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 3rd 2023

Jamile Shammo, MD, explains how she decides on the most appropriate treatment option for a patient with polycythemia vera.

Current Treatment Landscape for Patients With PV

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

July 3rd 2023

Drs Rampal and Yacoub details the currently available treatment options and reviews the rationale for use in patients with PV.

Risk Assessment for Patients with Polycythemia Vera (PV)

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

June 26th 2023

Dr Jamile Shammo describes how risk is assessed for patients with polycythemia vera.

An Overview of Myeloproliferative Neoplasms (MPNs)

Jamile Shammo, MD;Naveen Pemmaraju, MD;Raajit K. Rampal, MD, PhD;Abdulraheem Yacoub, MD

June 26th 2023

Experts provide an overview of myeloproliferative neoplasms, including the subtypes, process of diagnosis as well as reviewing the role of biomarkers.

Dr. Yacoub on Next Steps With Parsaclisib Plus Ruxolitinib in Myelofibrosis

Abdulraheem Yacoub, MD

June 1st 2021

Abdulraheem Yacoub, MD, discusses next steps with the combination of parsaclisib and ruxolitinib in myelofibrosis.

Dr. Yacoub on Efficacy and Safety Results With Parsaclisib in Myelofibrosis

Abdulraheem Yacoub, MD

May 6th 2021

Abdulraheem Yacoub, MD, discusses efficacy and safety results with parsaclisib in myelofibrosis.

Dr. Yacoub on the Rationale For Parsaclisib After Suboptimal Response to Ruxolitinib in Myelofibrosis

Abdulraheem Yacoub, MD

April 10th 2021

Abdulraheem Yacoub, MD, discusses the rationale behind examining parsaclisib following suboptimal response to ruxolitinib in patients with myelofibrosis.

Dr. Yacoub on Pegylated Interferon Treatment for PV

Abdulraheem Yacoub, MD

October 4th 2018

Abdulraheem Yacoub, MD, associate professor of medicine, University of Kansas Medical Center, discusses the potential of pegylated interferon treatment in patients with polycythemia vera.